2015
Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure
Gandhi PU, Gaggin HK, Belcher AM, Harisiades JE, Basile A, Falco A, Rosati A, Piscione F, Januzzi JL, Turco MC. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. Clinica Chimica Acta 2015, 445: 73-78. PMID: 25753466, DOI: 10.1016/j.cca.2015.02.048.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdaptor Proteins, Signal TransducingAdrenomedullinAgedAged, 80 and overApoptosis Regulatory ProteinsAtrial Natriuretic FactorBiomarkersErbB ReceptorsFemaleGene ExpressionHeart FailureHeart VentriclesHumansInterleukin-1 Receptor-Like 1 ProteinKidney Function TestsMalePrognosisReceptors, Cell SurfaceStroke VolumeSurvival AnalysisConceptsLeft ventricular ejection fractionBcl-2-associated athanogene 3Heart failureNatriuretic peptidePlasma concentrationsCox proportional hazards regressionWorse renal functionVentricular ejection fractionKaplan-Meier analysisProportional hazards regressionSignificant mortality predictorsCox proportional hazardsGenesis of cardiomyopathyHF prognosisHF patientsBaseline characteristicsPrimary endpointRenal functionEjection fractionHazards regressionMortality predictorsVital statusPrognostic valuePatientsProportional hazards
2014
Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study
Gaggin H, Bhardwaj A, Belcher A, Motiwala S, Gandhi P, Simon M, Kelly N, Anderson A, Garasic J, Danik S, Schwamm L, Gerszten R, van Kimmenade R, Januzzi J. Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. IJC Metabolic & Endocrine 2014, 5: 11-18. DOI: 10.1016/j.ijcme.2014.08.005.Peer-Reviewed Original ResearchAcute kidney injuryEnd pointRenal complicationsMajor adverse cardiovascular eventsProspective single-center trialLong-term adverse outcomesPeripheral arterial complicationsPeri-procedural eventsAdverse cardiovascular eventsCombined end pointPeri-procedural complicationsPrimary end pointSecondary end pointsChronic kidney diseaseSingle-center trialNumber of patientsIndividual end pointsCardiovascular Disease StudyArterial complicationsAngiographic characteristicsCardiovascular eventsKidney injuryBaseline characteristicsNeurological eventsRenal biomarkers